Abstract
UNLABELLED: ABSTRACT Background: Nintedanib plus docetaxel has proven an overall survival benefit over docetaxel monotherapy in second-line treatment of non-small-cell lung cancer of adenocarcinoma histology in the LUME-Lung 1 pivotal trial. No published trials have previously compared nintedanib plus docetaxel with agents - other than docetaxel - that are approved second-line treatments for non-small-cell lung cancer.
METHODS: The relative efficacy of nintedanib plus docetaxel versus second-line agents was evaluated by conducting a network meta-analysis of progression-free survival and overall survival.
RESULTS: Nine suitable studies were identified. The estimated probability of nintedanib plus docetaxel being the best treatment with regard to overall survival was 70% (versus 16% for pemetrexed, 10% for docetaxel and 3% for erlotinib). RESULTS for progression-free survival were similar.
CONCLUSION: In patients with advanced non-small-cell lung cancer of adenocarcinoma histology, results suggest that nintedanib plus docetaxel offers clinical benefit compared with docetaxel alone, when used as second-line treatment, and suggests that this combination may also add clinical benefit compared with erlotinib in this patient group.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Future oncology (London, England) |
| Vol/bind | 11 |
| Udgave nummer | 3 |
| Sider (fra-til) | 409-20 |
| Antal sider | 12 |
| ISSN | 1479-6694 |
| DOI | |
| Status | Udgivet - feb. 2015 |